There are updates and discussions about treatment options for metastatic bladder cancer, including the use of certain medications and regimens. Some treatments, such as sacituzumab govitecan, have had their indications withdrawn, while others, like the EV-302 regimen, continue to be supported by updated data. The field is also exploring new approaches, including palliative care and the potential role of circulating tumor dna in advanced bladder cancer.